MX2021010599A - Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares. - Google Patents
Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares.Info
- Publication number
- MX2021010599A MX2021010599A MX2021010599A MX2021010599A MX2021010599A MX 2021010599 A MX2021010599 A MX 2021010599A MX 2021010599 A MX2021010599 A MX 2021010599A MX 2021010599 A MX2021010599 A MX 2021010599A MX 2021010599 A MX2021010599 A MX 2021010599A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- disorders
- ocular diseases
- treating ocular
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Biological Depolymerization Polymers (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polyamides (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814198P | 2019-03-05 | 2019-03-05 | |
| PCT/US2020/021136 WO2020181060A1 (en) | 2019-03-05 | 2020-03-05 | Pharmaceutical compositions for treating ocular diseases or disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021010599A true MX2021010599A (es) | 2021-12-10 |
Family
ID=72337143
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021010599A MX2021010599A (es) | 2019-03-05 | 2020-03-05 | Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares. |
| MX2025002265A MX2025002265A (es) | 2019-03-05 | 2021-09-02 | Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025002265A MX2025002265A (es) | 2019-03-05 | 2021-09-02 | Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12478577B2 (https=) |
| EP (1) | EP3934646A4 (https=) |
| JP (3) | JP7570342B2 (https=) |
| KR (1) | KR20210135560A (https=) |
| CN (3) | CN118304422A (https=) |
| AU (1) | AU2020232314C1 (https=) |
| BR (1) | BR112021017436A2 (https=) |
| CA (1) | CA3132635A1 (https=) |
| MX (2) | MX2021010599A (https=) |
| WO (1) | WO2020181060A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210135560A (ko) | 2019-03-05 | 2021-11-15 | 에어리 파마슈티컬즈, 인코포레이티드 | 안구 질환 또는 장애를 치료하는 약학 조성물 |
| PT3861985T (pt) | 2020-02-06 | 2023-08-03 | Ocular Therapeutix Inc | Composições e métodos para tratar doenças oculares |
| PT3884929T (pt) | 2020-03-25 | 2023-08-09 | Ocular Therapeutix Inc | Implante ocular contendo um inibidor da tirosina cinase |
| US20230149387A1 (en) * | 2020-04-08 | 2023-05-18 | Aerie Pharmaceuticals, Inc. | Treatments |
| EP4329753A4 (en) | 2021-04-30 | 2025-02-26 | Perfuse Therapeutics, Inc. | PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES |
| US20240239750A1 (en) | 2021-05-05 | 2024-07-18 | Aerie Pharmaceuticals, Inc. | Pharmaceutical preparation |
| PE20260040A1 (es) | 2023-04-11 | 2026-01-09 | Ocular Therapeutix Inc | Implante ocular que contiene un inhibidor de la tirosina cinasa |
| WO2025146683A1 (en) | 2024-01-03 | 2025-07-10 | Lyotropic Delivery Systems Ltd. | Topical formulations for delivery of an active compound to the back of the eye |
| WO2025169089A1 (en) | 2024-02-05 | 2025-08-14 | Sun Pharmaceutical Industries Limited | Ophthalmic compositions of tyrosine kinase inhibitors and their uses |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2649672C (en) * | 2006-05-02 | 2015-07-07 | Medivas, Llc | Delivery of ophthalmologic agents to the exterior or interior of the eye |
| US20110158910A1 (en) | 2008-04-25 | 2011-06-30 | Aylvin Jorge Angelo Athanasius Dias | Microparticles comprising polymers with thioester bonds |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| CN110187549B (zh) * | 2010-06-22 | 2022-07-15 | 东洋纺株式会社 | 液晶显示装置、偏振板及偏振片保护膜 |
| BR112013018739A2 (pt) * | 2010-12-29 | 2019-09-24 | Jade Therapeutics Inc | sistema de distribuição de medicamento ocular |
| EP2704748B1 (en) * | 2011-05-02 | 2018-08-15 | DSM IP Assets B.V. | Bis-(alpha-amino-diol-diester) containing polyesteramide for ophtamology |
| JP6135870B2 (ja) * | 2011-05-02 | 2017-05-31 | ディーエスエム アイピー アセッツ ビー．ブイ． | 生分解性ポリマーを含む繊維 |
| WO2013126799A1 (en) * | 2012-02-22 | 2013-08-29 | Trustees Of Tufts College | Compositions and methods for ocular delivery of a therapeutic agent |
| CN104717962B (zh) * | 2012-10-02 | 2017-07-21 | 帝斯曼知识产权资产管理有限公司 | 包含蛋白质和可生物降解聚酯酰胺的药物递送组合物 |
| EP3702394B1 (en) | 2012-10-24 | 2023-11-22 | DSM IP Assets B.V. | Fibers comprising polyesteramide copolymers for drug delivery |
| EP2956096A1 (en) * | 2013-02-15 | 2015-12-23 | Allergan, Inc. | Sustained drug delivery implant |
| AU2014248460B2 (en) | 2013-04-01 | 2019-04-11 | Allergan, Inc. | Microsphere drug delivery system for sustained intraocular release |
| WO2015126477A1 (en) | 2013-11-08 | 2015-08-27 | Tyrx, Inc. | Polymeric drug delivery system for treating surgical complications |
| US20160296627A1 (en) * | 2013-12-06 | 2016-10-13 | Envisia Therapeutics Inc. | Intracameral implant for treatment of an ocular condition |
| CA2933900A1 (en) | 2013-12-20 | 2015-06-25 | Georgia Tech Research Corporation | Formulations and methods for targeted ocular delivery of therapeutic agents |
| US9931306B2 (en) | 2014-09-06 | 2018-04-03 | Integral Biosystems Llc | Methods and biocompatible compositions to achieve sustained drug release in the eye |
| US10434071B2 (en) | 2014-12-18 | 2019-10-08 | Dsm Ip Assets, B.V. | Drug delivery system for delivery of acid sensitivity drugs |
| CN108883070A (zh) | 2015-07-23 | 2018-11-23 | 爱瑞制药公司 | 用于治疗眼病的玻璃体内药物递送系统 |
| WO2017120600A1 (en) | 2016-01-08 | 2017-07-13 | Clearside Biomedical, Inc. | Compositions and methods of treating wet age-related macular degeneration |
| US20180117148A1 (en) * | 2016-10-28 | 2018-05-03 | Andrew J. Holman | Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders |
| AU2018226872A1 (en) | 2017-03-03 | 2019-09-05 | Macregen, Inc. | Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents |
| KR20210135560A (ko) | 2019-03-05 | 2021-11-15 | 에어리 파마슈티컬즈, 인코포레이티드 | 안구 질환 또는 장애를 치료하는 약학 조성물 |
-
2020
- 2020-03-05 KR KR1020217031760A patent/KR20210135560A/ko active Pending
- 2020-03-05 CA CA3132635A patent/CA3132635A1/en active Pending
- 2020-03-05 CN CN202410368231.1A patent/CN118304422A/zh active Pending
- 2020-03-05 CN CN202410368463.7A patent/CN118286445A/zh active Pending
- 2020-03-05 AU AU2020232314A patent/AU2020232314C1/en active Active
- 2020-03-05 WO PCT/US2020/021136 patent/WO2020181060A1/en not_active Ceased
- 2020-03-05 CN CN202080033265.5A patent/CN113784727B/zh active Active
- 2020-03-05 JP JP2021552571A patent/JP7570342B2/ja active Active
- 2020-03-05 EP EP20766052.3A patent/EP3934646A4/en active Pending
- 2020-03-05 BR BR112021017436A patent/BR112021017436A2/pt unknown
- 2020-03-05 US US16/810,149 patent/US12478577B2/en active Active
- 2020-03-05 MX MX2021010599A patent/MX2021010599A/es unknown
-
2021
- 2021-09-02 MX MX2025002265A patent/MX2025002265A/es unknown
-
2024
- 2024-10-08 JP JP2024176400A patent/JP7852008B2/ja active Active
- 2024-10-08 JP JP2024176401A patent/JP7838047B2/ja active Active
-
2025
- 2025-10-10 US US19/355,788 patent/US20260034056A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210135560A (ko) | 2021-11-15 |
| US12478577B2 (en) | 2025-11-25 |
| US20260034056A1 (en) | 2026-02-05 |
| CN118286445A (zh) | 2024-07-05 |
| JP7852008B2 (ja) | 2026-04-27 |
| US20200306182A1 (en) | 2020-10-01 |
| JP7570342B2 (ja) | 2024-10-21 |
| CN118304422A (zh) | 2024-07-09 |
| EP3934646A1 (en) | 2022-01-12 |
| JP2022523548A (ja) | 2022-04-25 |
| WO2020181060A1 (en) | 2020-09-10 |
| BR112021017436A2 (pt) | 2021-11-16 |
| CN113784727B (zh) | 2024-03-29 |
| CA3132635A1 (en) | 2020-09-10 |
| JP2025004161A (ja) | 2025-01-14 |
| AU2020232314B2 (en) | 2023-10-12 |
| JP7838047B2 (ja) | 2026-03-31 |
| JP2025004160A (ja) | 2025-01-14 |
| MX2025002265A (es) | 2025-04-02 |
| AU2020232314A1 (en) | 2021-09-30 |
| EP3934646A4 (en) | 2022-12-14 |
| AU2020232314C1 (en) | 2024-03-28 |
| CN113784727A (zh) | 2021-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025002265A (es) | Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares | |
| AU2018338608A1 (en) | Methods, compositions, and implantable elements comprising active cells | |
| PH12019502058A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| WO2021050953A8 (en) | Compositions and methods for the delivery of therapeutic biologics for treatment of disease | |
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| MX2023009682A (es) | Inhibidores de tyk2 y sus usos. | |
| WO2017177179A9 (en) | Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases | |
| WO2017070647A8 (en) | Nicotinamide for use in the treatment and prevention of ocular neurodegenerative disorder (e.g. glaucoma) | |
| TNSN08079A1 (en) | Pharmaceutical compositions for the treatment of inner ear disorders | |
| PH12023552741A1 (en) | Psilocybin Compositions, Methods Of Making And Methods Of Using The Same | |
| PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
| WO2010081091A3 (en) | Therapeutic compositions for treatment of corneal disorders | |
| MX2025002953A (es) | Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| GB2556500A (en) | Compositions and methods for reducing visual loss | |
| WO2022175746A8 (en) | Tyk2 inhibitors and uses thereof | |
| WO2016100738A3 (en) | Antifibrotic activity of gas6 inhibitor | |
| CR20220570A (es) | Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas | |
| WO2019175260A3 (en) | Modified oligonucleotides for use in treatment of tauopathies | |
| MX2023003993A (es) | Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina. | |
| WO2023009615A3 (en) | Methods and compositions for treating or preventing neurological injury or neurological disorders | |
| MX2025014320A (es) | Compuestos nitrogenados aromaticos, metodos de preparacion y usos medicinales | |
| EA201790382A1 (ru) | Способы лечения периимплантита | |
| MX2021005421A (es) | Macrólidos de 13 miembros con sustitución cíclica en c10 y usos de los mismos. |